Epidemiological burden of postmenopausal osteoporosis in France from 2010 to 2020: estimations from a disease model
Tóm tắt
This article estimates the present and future burden of postmenopausal osteoporosis in France in women aged 50 years and over. We adapted an existing model developed for Sweden to France. For each year of the study from 1970 to 2020, the ‘incident cohort’ (women experiencing a first osteoporotic fracture) was identified and run through a Markov model using annual cycles. Health states were based on the number of fractures (hip, vertebral, non-hip non-vertebral) and deaths. Transition probabilities reflected fracture site-specific risks of subsequent fractures and of death. Country-specific model inputs included population size and life tables from 1970 to 2020 and incidence of hip fracture. The model estimated that the number of postmenopausal osteoporotic women was expected to increase from 3.0 million to 3.4 million between 2010 and 2020 (+15.3 %). Assuming that the incidence of fracture by age group does not change over time, the model predicted that the overall number of osteoporotic fractures would increase from 204,234 fractures in 2010 to 241,261 in 2020 (+18.1 %), hip (20.3 %), vertebral (19.0 %) and non-hip non-vertebral fractures (17.0 %). The aging of the population is expected to drive a marked increase in the prevalence of osteoporosis and in the number of osteoporotic fractures. These data may assist future planning for appropriate heath care provision.
Tài liệu tham khảo
Anonymous (1993) Consensus development conference: diagnosis, prophylaxis, and treatment of osteoporosis. Am J Med 94:646–650
Kanis JA on behalf of the World Health Organisation Scientific Group (2007) Assessment of osteoporosis at the primary health care level. World Health Organisation Collaborating Center for Metabolic Bone diseases University of Sheffield, UK. Available at. http://www.shef.ac.uk/FRAX/pdfs/WHO_Technical_Report.pdf
Programme National Nutrition Santé (PNNS) (2010) Rapport du Haut Comité de santé Publique : “Pour une politique nutritionnelle de santé publique en France”. DREES
Maravic M, Taupin P, Landais P, Roux C (2011) Change in hip fracture incidence over the last 6 years in France. Osteoporos Int 22:797–801
Maravic M, Le BC, Landais P, Fardellone P (2005) Incidence and cost of osteoporotic fractures in France during 2001. A methodological approach by the national hospital database. Osteoporos Int 16:1475–1480
Gauthier A, Kanis JA, Martin M, Compston J, Borgstrom F, Cooper C, McCloskey E (2010) Development and validation of a disease model for postmenopausal osteoporosis. Osteoporos Int 22:771–780
World Health Organisation (1994) Assessment of fracture risk and its application to screening for postmenauposal osteoporosis. World Health Organisation, Geneva Technical Report series no. 843:1–129
Melton LJ III, Thamer M, Ray NF, Chan JK, Chesnut CH III, Einhorn TA, Johnston CC, Raisz LG, Silverman SL, Siris ES (1997) Fractures attributable to osteoporosis: report from the National Osteoporosis Foundation. J Bone Miner Res 12:16–23
Kanis JA, Oden A, Johnell O, Jonsson B, De LC, Dawson A (2001) The burden of osteoporotic fractures: a method for setting intervention thresholds. Osteoporos Int 12:417–427
Kanis JA, Oden A, Johnell O, De LC, Jonsson B, Oglesby AK (2003) The components of excess mortality after hip fracture. Bone 32:468–473
Kanis JA, Oden A, Johnell O, De LC, Jonsson B (2004) Excess mortality after hospitalisation for vertebral fracture. Osteoporos Int 15:108–112
Anonymous (2009) Institut National de la Statistique et des Etudes Economiques. http://www.insee.fr/fr/themes/detail.asp?ref_id=ir-sd2006&page=irweb/sd2006/dd/sd2006_population.htm
Anonymous (2009) Institut National des Edudes Demographiques. http://www.ined.fr/cdrom_vallin_mesle/Donnees-de-base/Populations/Tableau-I-C-1.xls
Couris CM, Chapurlat RD, Kanis JA, Burlet N, Delmas PD, Schott AM (2012) FRAX probabilities and risk of major osteoporotic fracture in France. Osteopooros Int 23:2321–7
Stevenson M, Jones ML, De NE, Brewer N, Davis S, Oakley J (2005) A systematic review and economic evaluation of alendronate, etidronate, risedronate, raloxifene and teriparatide for the prevention and treatment of postmenopausal osteoporosis. Health Technol Assess 9:1–160
Klotzbuecher CM, Ross PD, Landsman PB, Abbott TA III, Berger M (2000) Patients with prior fractures have an increased risk of future fractures: a summary of the literature and statistical synthesis. J Bone Miner Res 15:721–739
Kanis JA, Johnell O, Oden A, Sembo I, Redlund-Johnell I, Dawson A, De LC, Jonsson B (2000) Long-term risk of osteoporotic fracture in Malmo. Osteoporos Int 11:669–674
Marshall D, Johnell O, Wedel H (1996) Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ 312:1254–1259
Kanis JA, Johnell O, De LC, Johansson H, Oden A, Delmas P, Eisman J, Fujiwara S, Garnero P, Kroger H, McCloskey EV, Mellstrom D, Melton LJ, Pols H, Reeve J, Silman A, Tenenhouse A (2004) A meta-analysis of previous fracture and subsequent fracture risk. Bone 35:375–382
Looker AC, Wahner HW, Dunn WL, Calvo MS, Harris TB, Heyse SP, Johnston CC Jr, Lindsay R (1998) Updated data on proximal femur bone mineral levels of US adults. Osteoporos Int 8:468–489
Haute Autorité de la Santé (2006) Prévention, diagnostic et traitement de l’ostéoporose. Haute Autorité de la Santé
Cooper C, Cole ZA, Holroyd CR, Earl SC, Harvey NC, Dennison EM, Melton LJ, Cummings SR, Kanis JA (2011) Secular trends in the incidence of hip and other osteoporotic fractures. Osteoporos Int 22:1277–1288
Gullberg B, Johnell O, Kanis JA (1997) World-wide projections for hip fracture. Osteoporos Int 7:407–413
Melton LJ III, Kanis JA, Johnell O (2005) Potential impact of osteoporosis treatment on hip fracture trends. J Bone Miner Res 20:895–897
Kanis JA, Hans D, Cooper C, Baim S, Bilezikian JP, Binkley N, Cauley JA, Compston JE, Dawson-Hughes B, El-Hajj FG, Johansson H, Leslie WD, Lewiecki EM, Luckey M, Oden A, Papapoulos SE, Poiana C, Rizzoli R, Wahl DA, McCloskey EV (2011) Interpretation and use of FRAX in clinical practice. Osteoporos Int 22:2395–2411